Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs ClearPoint Neuro Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.34, while ClearPoint Neuro Inc trades at $17.39 (market cap $524.82M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | CLPT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $29.60 |
52-Week Low | $43.28 | $8.66 |
Market Cap | — | $524.82M |
Enterprise Value | — | $552.81M |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.
The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.
Trailing returns across standard periods
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →